These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
546 related articles for article (PubMed ID: 33730602)
1. Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. Romeo B; Hermand M; Pétillion A; Karila L; Benyamina A J Psychiatr Res; 2021 May; 137():273-282. PubMed ID: 33730602 [TBL] [Abstract][Full Text] [Related]
2. [Efficacy of psychedelics in psychiatry, a systematic review of the literature]. Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297 [TBL] [Abstract][Full Text] [Related]
3. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078 [TBL] [Abstract][Full Text] [Related]
4. Classical psychedelics for the treatment of depression and anxiety: A systematic review. Muttoni S; Ardissino M; John C J Affect Disord; 2019 Nov; 258():11-24. PubMed ID: 31382100 [TBL] [Abstract][Full Text] [Related]
7. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555 [TBL] [Abstract][Full Text] [Related]
8. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders. Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717 [TBL] [Abstract][Full Text] [Related]
9. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. Leger RF; Unterwald EM J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567 [TBL] [Abstract][Full Text] [Related]
10. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets. Sousa TR; Rema J; Machado S; Novais F Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736 [TBL] [Abstract][Full Text] [Related]
11. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation. Johnson MW Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Andersen KAA; Carhart-Harris R; Nutt DJ; Erritzoe D Acta Psychiatr Scand; 2021 Feb; 143(2):101-118. PubMed ID: 33125716 [TBL] [Abstract][Full Text] [Related]
13. Role of Psychedelics in Treatment-Resistant Depression. Kamal S; Jha MK; Radhakrishnan R Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular safety of psychedelic medicine: current status and future directions. Wsół A Pharmacol Rep; 2023 Dec; 75(6):1362-1380. PubMed ID: 37874530 [TBL] [Abstract][Full Text] [Related]
15. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. Chi T; Gold JA J Neurol Sci; 2020 Apr; 411():116715. PubMed ID: 32044687 [TBL] [Abstract][Full Text] [Related]
16. Psychedelic drugs for psychiatric disorders. da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696 [TBL] [Abstract][Full Text] [Related]
17. [Psychedelics in the treatment of depression, anxiety, and obsessive-compulsive disorder]. Breeksema JJ; van den Brink W; Veraart JKE; Smith-Apeldoorn SY; Vermetten E; Schoevers RA Tijdschr Psychiatr; 2020; 62(8):618-628. PubMed ID: 32816290 [TBL] [Abstract][Full Text] [Related]
18. The Therapeutic Potential of Psilocybin. Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L Molecules; 2021 May; 26(10):. PubMed ID: 34063505 [TBL] [Abstract][Full Text] [Related]
19. Psilocybin for the Treatment of Obsessive-Compulsive Disorders. Ehrmann K; Allen JJB; Moreno FA Curr Top Behav Neurosci; 2022; 56():247-259. PubMed ID: 34784024 [TBL] [Abstract][Full Text] [Related]
20. Psychedelic perceptions: mental health service user attitudes to psilocybin therapy. Corrigan K; Haran M; McCandliss C; McManus R; Cleary S; Trant R; Kelly Y; Ledden K; Rush G; O'Keane V; Kelly JR Ir J Med Sci; 2022 Jun; 191(3):1385-1397. PubMed ID: 34131812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]